Skip to main content

Advertisement

SpringerLink
Log in

Personalized Medicine in Systemic Sclerosis: Facts and Promises

  • SCLERODERMA (J VARGA, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The concept of personalized medicine has led to a paradigm shift in recent years. It integrates multiple clinical and biological levels of investigation aimed at offering the best possible and patient-tailored healthcare. This holds great potential in a rare and heterogeneous disease such as systemic sclerosis (SSc). The development of validated clinical screening algorithms and the identification of predictors for disease outcomes can help in stratifying patients according to their individual risk of progression. The ongoing search for biomarkers and key pathogenic molecules has brought valuable insights into molecular networks operative in SSc. In parallel, genetic and genomic studies have revealed new SSc susceptibility loci and validated gene expression profiles that might identify patients benefiting from specific therapies. In this review, we focus on recent findings relevant for the concept of personalized medicine in patients with SSc.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Tutton R. Personalizing medicine: futures, present and past. Soc Sci Med. 2012;75(10):1721–8.

    Article  PubMed  Google Scholar 

  2. Personalized medicine for the European Citizen. Towards more precise medicine for the diagnosis, treatment and prevention of disease. Available at http://www.esf.org/fileadmin/Public_documents/Publications/Personalised_Medicine.pdf. Accessed October 2013. This defines personalized medicine as a priority for European research.

  3. Varga J. Systemic sclerosis. An update. Bull NYU Hosp Jt Dis. 2008;66(3):198–202.

    PubMed  Google Scholar 

  4. Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37(4):223–35.

    Article  PubMed  Google Scholar 

  5. Minier T, Péntek M, Brodszky V, et al. Cost-of-ilness of patients with systemic sclerosis in a tertiary care center. Rheumatology (Oxford). 2010;49(10):1920–8.

    Article  Google Scholar 

  6. Allanore Y, Avouac J, Kahan A. Systemic sclerosis: an update in 2008. Joint Bone Spine. 2008;75(6):650–5.

    Article  PubMed  Google Scholar 

  7. Steen V. Targeted therapy for systemic sclerosis. Autoimmun Rev. 2006;5(2):122–4.

    Article  CAS  PubMed  Google Scholar 

  8. Derk C. Disease-modifying drugs for systemic sclerosis: why have we not found them yet? Expert Rev Clin Immunol. 2011;7(4):399–401.

    Article  PubMed  Google Scholar 

  9. Maurer B, Distler O. Emerging targeted therapies in scleroderma lung and skin fibrosis. Best Pract Res Clin Rheumatol. 2011;25(6):843–58.

    Article  CAS  PubMed  Google Scholar 

  10. Iwamoto N, Distler O. Molecular targets for therapy in systemic sclerosis. Fibrogenesis Tissue Repair. 2012;5 Suppl 1:S19.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Jordan S, Chung J, Distler O. Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol. 2013;25(6):679–85.

    Article  CAS  PubMed  Google Scholar 

  12. Abigano G, Buch M, Emery P. Biomarkers in the management of scleroderma: an update. Curr Rheumatol Rep. 2011;13(1):4–12.

    Article  Google Scholar 

  13. Merkel PA, Silliman NP, Clements PJ, et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma an individual patient meta-analysis of 629 subjects with diffuse scleroderma. Arthritis Rheum. 2012;64(10):3420–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Castro S, Jimenez S. Biomarkers in systemic sclerosis. Biomarkers Med. 2010;4(1):133–47.

    Article  CAS  Google Scholar 

  15. Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis. Application of a latent linear trajectory model. Arthritis Rheum. 2007;56(7):2422–31.

    Article  PubMed  Google Scholar 

  16. Maurer B, Graf N, Michel B, et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 2014, in revision. This EUSTAR study developed evidence-based models to predict worsening of skin fibrosis.

  17. Celeste S, Santaniello A, Caronni M, et al. Carbohydrate antigen 15.3 as a serum biomarker of interstitial lung disease in systemic sclerosis patients. Eur J Intern Med. 2013;24(7):671–6.

    Article  CAS  PubMed  Google Scholar 

  18. Lee CG, Herzog EL, Ahangari F, et al. Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-b1 signaling. J Immunol. 2012;189(5):2635–44.

    Article  CAS  PubMed  Google Scholar 

  19. van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014;370(5):433–43.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Tiev KP, Hua-Huy T, Rivière S, et al. High alveolar concentration of nitric oxide is associated with alveolitis in scleroderma. Nitric Oxide. 2013;28:65–70.

    Article  CAS  PubMed  Google Scholar 

  21. Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long term survival in systemic sclerosis. Arthritis Rheumatol. 2014 Mar 3. [Epub ahead of print].

  22. Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). 2013;52(1):155–60. Confirms results from Goh et al. (23) that advanced lung involvement on HRCT is a major prognostic factor in SSc-ILD.

    Article  Google Scholar 

  23. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248–54.

    Article  PubMed  Google Scholar 

  24. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620–8.

    Article  CAS  PubMed  Google Scholar 

  25. Mihai C, Landewé R, van der Heijde D, et al. Predictive value of history of digital ulcers in a EUSTAR cohort of patients with systemic sclerosis. [abstract 13-3570]. Presented at EULAR, 12–15 June 2013, Madrid, Spain.

  26. Avouac J, Meune C, Ruiz B, et al. Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. Ann Rheum Dis. 2012;71(3):394–9.

    Article  CAS  PubMed  Google Scholar 

  27. Alivernini S, De Santis M, Tolusso B, et al. Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. J Am Acad Dermatol. 2009;60(3):426–35.

    Article  PubMed  Google Scholar 

  28. Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis. 2012;71(7):1235–42.

    Article  CAS  PubMed  Google Scholar 

  29. Sebastiani M, Manfredi A, Vukatana G, et al. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study. Ann Rheum Dis. 2012;71(1):67–70.

    Article  CAS  PubMed  Google Scholar 

  30. Sebastiani M, Manfredi A, Lo Monaco A, et al. Capillaroscopic Skin Ulcers Risk Index (CSURI) calculated with different videocapillaroscopy devices: how its predictive values change. Clin Exp Rheumatol. 2013;31(2 Suppl 76):115–7.

    PubMed  Google Scholar 

  31. Smith V, De Keyser F, Pizzorni C, et al. Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann Rheum Dis. 2011;70(1):180–3.

    Article  PubMed  Google Scholar 

  32. Cutolo M, Herrick A, Distler O, et al. Nailfold videocapillaroscopy and other predictive factors associated with new digital ulcers in systemic sclerosis: results from the CAP study. [abstract PS04]. Presented at the 3rd Systemic Sclerosis World Congress. Rome, Italy; February 6–8, 2014.

  33. Lefévre G, Dauchet L, Hachulla E, et al. Survival and prognostic factors in systemic sclerosis–associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65(9):2412–23.

    Article  PubMed  Google Scholar 

  34. Chung L, Domsic R, Bharathi L, et al. Survival and predictors of mortality in systemic sclerosis associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res. 2014;66(3):489–95.

    Article  Google Scholar 

  35. Gladue H, Altorok N, Towsend W, et al. Screening and diagnostic modalities for connective tissue disease - associated pulmonary arterial hypertension: a systematic review. Semin Arthritis Rheum. 2014;43(4):536–41.

    Article  PubMed  Google Scholar 

  36. Codullo V, Caporali R, Cuomo G, et al. Stress doppler echocardiography in systemic sclerosis. Evidence for a role in the prediction of pulmonary hypertension. Arthritis Rheum. 2013;65(9):2403–11.

    Article  PubMed  Google Scholar 

  37. Coghlan JG. Stress echocardiography and Cochin risk prediction score for the prediction of pulmonary arterial hypertension in scleroderma: not yet ready for prime time. Arthritis Rheum. 2013;65(9):2236–9.

    Article  PubMed  Google Scholar 

  38. Coghlan JG, Denton C, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis:the DETECT study. Ann Rheum Dis. 2013 May 18. [Epub ahead of print]. The DETECT study developed an evidence-based algorithm for the early detection of PAH in high-risk patients with SSc.

  39. Khanna D, Gladue H, Channick R, et al. Recommendations for screening and detection of connective tissue disease–associated pulmonary arterial hypertension. Arthritis Rheum. 2013;65(12):3194–201.

    Article  PubMed  Google Scholar 

  40. Avouac J, Airò P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010;37(11):2290–8.

    Article  PubMed  Google Scholar 

  41. Avouac J, Huscher D, Furst DE, et al. Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. Ann Rheum Dis. 2014;73(1):191–7.

    Article  PubMed  Google Scholar 

  42. Mayes MD. The genetics of scleroderma: looking into the postgenomic era. Curr Opin Rheumatol. 2012;24(6):677–84.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Allanore Y, Saad M, Dieude P, et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet. 2011;7(7):e1002091.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet. 2010;42(5):426–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Zhou X, Lee JE, Arnett FC, et al. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. Arthritis Rheum. 2009;60(12):3807–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Gorlova O, Martin JE, Rueda B, et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet. 2011;7(7):e1002178.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Assassi S, Radstake TR, Mayes MD, et al. Genetics of scleroderma: implications for personalized medicine? BMC Med. 2013;11:9.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One. 2008;3(7):e2696.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Pendergrass A, Lemaire R, Francis IP, et al. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol. 2012;132(5):1363–73.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Hinchcliff M, Wood T, Mahoney JM, et al. SSc intrinsic subset classification in patients that demonstrate clinical improvement during treatment. [abstract S.1.7]. Presented at the 3rd Systemic Sclerosis World Congress. Rome, Italy; February 6–8, 2014.

  51. Bhattacharyya S, Sargent JL, Du P, et al. Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PLoS One. 2011;6(9):e23082.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Greenblatt MB, Aliprantis AO. The Immune Pathogenesis of Scleroderma: context is everything. Curr Rheumatol Rep. 2013;15(1):297.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Hunzelmann N, Brinckmann J. What are the new milestones in the pathogenesis of systemic sclerosis? Ann Rheum Dis. 2010;69(Suppl I):i52–6.

    Article  CAS  PubMed  Google Scholar 

  54. Sargent JL, Milano A, Bhattacharyya S, et al. A TGFb-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol. 2010;130(3):694–705.

    Article  CAS  PubMed  Google Scholar 

  55. Farina G, Lafyatis D, Lemaire R, et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2010;62(2):580–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Greenblatt MB, Sargent JL, Farina G, et al. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL-2 as disease subset-specific targets. Am J Pathol. 2012;180(3):1080–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Leask A. Egr-ly awaiting a “personalized medicine” approach to treat scleroderma. J Cell Commun Signal. 2012;6(2):111–3.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Sargent JL, Milano A, Connolly MK, et al. Scleroderma gene expression and pathway signatures. Curr Rheumatol Rep. 2008;10(3):205–11.

    Article  CAS  PubMed  Google Scholar 

  59. Hsu E, Shi H, Jordan RM, et al. Lung tissues in systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary artery hypertension. Arthritis Rheum. 2011;63(3):783–94. First study describing gene expression patterns based on arrays in lung tissue from SSc patients.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Liao WL, Tsai FJ. Personalized medicine: a paradigm shift in healthcare. BioMedicine. 2013;3(2):66–72.

    Article  Google Scholar 

  61. Sargent J, Whitfield M. Capturing the heterogeneity in systemic sclerosis with genomewide expression profiling. Expert Rev Clin Immunol. 2011;7(4):463–73.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  62. Chung L, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to Imatinib mesylate in systemic sclerosis. Arthritis Rheum. 2009;60(2):584–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Maurer B, Distler A, Dees C, et al. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Ann Rheum Dis. 2013;72(12):2039–46.

    Article  CAS  PubMed  Google Scholar 

  64. Hinchcliff M, Huang CC, Wood TA, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol. 2013;133(8):1979–89. This paper shows a correlation between the gene expression profile and response to MMF treatment.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Roth MD, Tseng CH, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related intesrtitial lung disease. Arthritis Rheum. 2011;63(9):2797–808.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Lambova S, Muller-Ladner U. Chapter79: Systemic Sclerosis. Genomic and Personalized Medicine 2nd Edition. Edited by Ginsburg GS and Willard HF. Oxford: Academic Press; 2012:955–69.

  67. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–66.

    Article  CAS  PubMed  Google Scholar 

  68. Rueda B, Gourh P, Broen J, et al. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann Rheum Dis. 2010;69(4):700–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Bossini-Castillo L, Broen JC, Simeon CP, et al. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis. 2011;70(4):638–41.

    Article  CAS  PubMed  Google Scholar 

  70. Dieudé P, Guedj M, Wipff J, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum. 2009;60(1):225–33.

    Article  PubMed  Google Scholar 

  71. Dieudé P, Guedj M, Wipff J, et al. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis. 2010;69(11):1958–64.

    Article  PubMed  Google Scholar 

  72. Bossini-Castillo L, Martin JE, Broen J, et al. Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study. Ann Rheum Dis. 2013;72(4):602–7.

    Article  CAS  PubMed  Google Scholar 

  73. Dieudé P, Bouaziz M, Guedj M, et al. Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis Rheum. 2011;63(12):3979–87.

    Article  PubMed  Google Scholar 

  74. Carmona FD, Cénit MC, Diaz-Gallo LM, et al. New insight on the Xq28 association with systemic sclerosis. Ann Rheum Dis. 2013;72(12):2032–8.

    Article  CAS  PubMed  Google Scholar 

  75. Cénit MC, Simeon CP, Vonk MC, et al. Influence of the IL6 gene in susceptibility to systemic sclerosis. J Rheumatol. 2012;39(12):2294–302.

    Article  PubMed  Google Scholar 

  76. Martin JE, Broen JC, Carmona FD, et al. Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Hum Mol Genet. 2012;21(12):2825–35.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  77. Bossini-Castillo L, Martin JE, Broen J, et al. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet. 2012;21(4):926–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  78. Manetti M, Allanore Y, Saad M, et al. Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. Ann Rheum Dis. 2012;71(6):1034–41.

    Article  CAS  PubMed  Google Scholar 

  79. Diaz-Gallo LM, Simeon C, Broen J, et al. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann Rheum Dis. 2013;72(7):1233–8.

    Article  CAS  PubMed  Google Scholar 

  80. Bossini-Castillo L, Simeon C, Beretta L, et al. A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Res Ther. 2012;14(2):R85.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Manetti M, Allanore Y, Revillod L, et al. A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. Arthritis Rheum. 2011;63(1):247–56.

    Article  CAS  PubMed  Google Scholar 

  82. Wipff J, Dieudé P, Guedj M, et al. Association of a KCNA5 gene polymorphism with systemic sclerosis–associated pulmonary arterial hypertension in the European Caucasian population. Arthritis Rheum. 2010;62(10):3093–100.

    Article  CAS  PubMed  Google Scholar 

  83. Sharif R, Mayes M, Tan FK, et al. IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis. 2012;71(7):1197–202.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Carina Mihai declares that she has no conflict of interest.

Rucsandra Dobrota has received the following grants: Articulum Fellowship 2014, EULAR training bursary 2013, Research funding from Actelion Pharmaceuticals and paid travel accommodations from Actelion Pharmaceuticals.

Oliver Distler has received consultancy fees from Actelion, Pfizer, Ergonex, BMS, Bayer, United BioSource Corporation, Roche/Genentech, Medac, Biovitrium, Boehringer Ingelheim Pharma, Novartis, 4 D Science, Active Biotec, Sinoxa, Sanofi-Aventis, Serodapharm, GSK, and Epipharm to investigate potential treatments of scleroderma and its complications. He also has received grants from Actelion Pharmaceuticals, Ltd., Pfizer, Ergonex, and Sanofi-Aventis to investigate potential treatments of scleroderma and its complications. Dr. Distler has also received payment for development of educational presentations from Actelion and has a patent for mir-29 for the treatment of systemic sclerosis.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Rheumatology, University Hospital Zurich, Gloriastrasse 25, 8091, Zurich, Switzerland

    Rucsandra Dobrota & Oliver Distler

  2. Department of Internal Medicine and Rheumatology, Dr.I. Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

    Rucsandra Dobrota & Carina Mihai

Authors
  1. Rucsandra Dobrota
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carina Mihai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Oliver Distler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oliver Distler.

Additional information

This article is part of the Topical Collection on Scleroderma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dobrota, R., Mihai, C. & Distler, O. Personalized Medicine in Systemic Sclerosis: Facts and Promises. Curr Rheumatol Rep 16, 425 (2014). https://doi.org/10.1007/s11926-014-0425-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-014-0425-8

Keywords

Search

Navigation